Skip to content

Study · Randomized controlled trial · n = 8 · 2007

4 results

Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women.

Dhillo WS, Chaudhri OB, Thompson EL, Murphy KG, Patterson M, Ramachandran R, Nijher GK, Amber V, Kokkinos A, Donaldson M, Ghatei MA, Bloom SR

The Journal of clinical endocrinology and metabolism17 Jul 2007Cited by 202 (Europe PMC)

PMID17635940 (opens in a new tab)DOI10.1210/jc.2007-1116 (opens in a new tab)PepBankPUB-17635940
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy women, kisspeptin‑54 increased plasma LH compared with saline in all phases of the menstrual cycle.

    In plain wordsIn healthy women, kisspeptin‑54 raised LH more than saline in every phase of the menstrual cycle.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreasePlasma LH versus saline in all cycle phases
    Study

    n = 8

    Comparator
    Saline
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.4 nmol/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    2) Kisspeptin-54 increased plasma LH compared with saline injection in all phases of the cycle.
    2 context sentences
    Summary · context
    Subjects were healthy female volunteers with regular menstrual cycles.
    Summary · context
    1) Volunteers received a sc bolus injection of kisspeptin-54 (0, 0.2, 0.4, 0.8, 1.6, 3.2, and 6.4 nmol/kg; n = 3-4 per dose) in the follicular phase; and 2) volunteers (n = 8) received a sc bolus injection of either kisspeptin-54 (0.4 nmol/kg) or saline in random order during each phase of the menstrual cycle.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy women, the LH increase after kisspeptin‑54 was greatest in the preovulatory phase compared with the follicular phase.

    In plain wordsIn healthy women, kisspeptin‑54 raised LH most just before ovulation and least early in the cycle.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseLH increase in preovulatory vs follicular phase
    Study

    n = 8

    Comparator
    Follicular phase
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.4 nmol/kg · subcutaneousAs given in this study (human).

    Measurements

    Mean increase in LH over baseline
    20.64 IU/liter
    preovulatory phase
    Mean increase in LH over baseline
    0.12 IU/liter
    follicular phase

    Source sentences

    Summary
    The effect of kisspeptin was greatest in the preovulatory phase and least in the follicular phase of the cycle [mean increase in LH over baseline (IU/liter) +/- sem for follicular phase was 0.12 +/- 0.17; preovulatory phase, 20.64 +/- 2.91 (P < 0.001 vs. follicular phase); luteal phase, 2.17 +/- 0.7…
    2 context sentences
    Summary · context
    Subjects were healthy female volunteers with regular menstrual cycles.
    Summary · context
    1) Volunteers received a sc bolus injection of kisspeptin-54 (0, 0.2, 0.4, 0.8, 1.6, 3.2, and 6.4 nmol/kg; n = 3-4 per dose) in the follicular phase; and 2) volunteers (n = 8) received a sc bolus injection of either kisspeptin-54 (0.4 nmol/kg) or saline in random order during each phase of the menstrual cycle.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy women, the LH increase after kisspeptin‑54 was larger in the luteal phase than in the follicular phase.

    In plain wordsIn healthy women, kisspeptin‑54 raised LH more in the second half of the cycle than early in the cycle.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseLH increase in luteal vs follicular phase
    Study

    n = 8

    Comparator
    Follicular phase
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.4 nmol/kg · subcutaneousAs given in this study (human).

    Measurements

    Mean increase in LH over baseline
    2.17 IU/liter
    luteal phase
    Mean increase in LH over baseline
    0.12 IU/liter
    follicular phase

    Source sentences

    Summary
    The effect of kisspeptin was greatest in the preovulatory phase and least in the follicular phase of the cycle [mean increase in LH over baseline (IU/liter) +/- sem for follicular phase was 0.12 +/- 0.17; preovulatory phase, 20.64 +/- 2.91 (P < 0.001 vs. follicular phase); luteal phase, 2.17 +/- 0.7…
    2 context sentences
    Summary · context
    Subjects were healthy female volunteers with regular menstrual cycles.
    Summary · context
    1) Volunteers received a sc bolus injection of kisspeptin-54 (0, 0.2, 0.4, 0.8, 1.6, 3.2, and 6.4 nmol/kg; n = 3-4 per dose) in the follicular phase; and 2) volunteers (n = 8) received a sc bolus injection of either kisspeptin-54 (0.4 nmol/kg) or saline in random order during each phase of the menstrual cycle.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy women in the follicular phase, kisspeptin‑54 caused a dose-dependent increase in mean LH at doses from 0.2 to 6.4 nmol/kg.

    In plain wordsIn healthy women, kisspeptin‑54 raised LH more as the dose went up.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseMean LH over time by kisspeptin-54 dose
    Study

    n: not reported in source

    Comparator
    0 nmol/kg
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.2-6.4 nmol/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    1) Kisspeptin-54 caused a dose-dependent increase in mean LH over time at doses from 0.2-6.4 nmol/kg.
    2 context sentences
    Summary · context
    Subjects were healthy female volunteers with regular menstrual cycles.
    Summary · context
    1) Volunteers received a sc bolus injection of kisspeptin-54 (0, 0.2, 0.4, 0.8, 1.6, 3.2, and 6.4 nmol/kg; n = 3-4 per dose) in the follicular phase; and 2) volunteers (n = 8) received a sc bolus injection of either kisspeptin-54 (0.4 nmol/kg) or saline in random order during each phase of the menstrual cycle.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.